Truist Securities Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregory Fraser has maintained a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased the price target from $72 to $80.
March 01, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Buy rating on ANI Pharmaceuticals and raised the price target from $72 to $80.
The upgrade in the price target by a reputable analyst like Gregory Fraser suggests a strong confidence in ANI Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100